Investigational Medication for AATD & COPD

Trial Objective

Our researchers want to find out if an investigational medication, a hyaluronic acid inhalation solution, can be used to treat alpha-1 antitrypsin deficiency (AATD) and emphysema. A common substance made by the human body, hyaluronic acid is found in the highest concentrations in the skin, joint fluid and eye.

Investigational Medication for AATD and COPD

In the lungs, hyaluronic acid is in the alveoli and the smallest airways. Hyaluronic acid has been used extensively in humans through injection to a specific area, such as the eyes, or to the body as a whole. Overall, patients have experienced few side effects. Giving patients hyaluronic acid through inhalation to the lungs has been done on a limited basis.


This trial is active and currently recruiting.

How to Participate

For more information, call 303.398.2622 or complete the form below.

Who Can Participate

Adults who have alpha-1 antitrypsin deficiency (AATD) and chronic obstructive pulmonary disease (COPD) are eligible to participate.

Estimated Time Commitment

5 visits

A total of five clinic visits, which could total up to 22.5 hours: Visit 1 Screening (two weeks to one day before the trial begins), Visit 2 (Day 1 of the trial), Visit 3 (Day 14), Visit 4 (Day 28) and Visit 5/final visit (Day 35).

Trial Location

National Jewish Main Campus, Denver, CO



Trial Sponsors

MatRx Therapeutics




Any Gender

Request More Information